Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

OBJECTIVE: To assess the impact of certolizumab pegol (CZP) on patient-reported outcomes (PROs) in rheumatoid arthritis (RA), and to interpret these results using number needed to treat (NNT), and associations between PRO responses and longer term outcomes. METHODS: A total of 619 patients with acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Smolen, Josef S, van Vollenhoven, Ronald F, Mease, Philip, Burmester, Gerd R, Hiepe, Falk, Khanna, Dinesh, Nikaï, Enkeleida, Coteur, Geoffroy, Schiff, Michael
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086050/
https://www.ncbi.nlm.nih.gov/pubmed/21415050
http://dx.doi.org/10.1136/ard.2010.143586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086050/
https://www.ncbi.nlm.nih.gov/pubmed/21415050
http://dx.doi.org/10.1136/ard.2010.143586

Ejemplares similares